Upstream Bio (UPB) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Upstream Bio is the larger company by market cap ($249.2 million vs $248.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | UPB | VCRE |
|---|---|---|
| Share price | $4.55 | $8.82 |
| Market cap | $249.21M | $248.41M |
| 1-day change | -1.30% | +1.85% |
| YTD return | -83.24% | — |
| 1-year return | -75.95% | — |
| EPS (TTM) | $-2.88 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.68 | $17.80 |
| 52-week low | $4.37 | $7.88 |
| Distance from 52-week high | -86.49% | -50.45% |
| Analyst consensus | none | none |
| Avg. price target upside | +584.40% | +275.96% |
| Average volume | 610.08K | 16.22K |
| Shares outstanding | 54.77M | 28.16M |
| Employees | 75 | 46 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Upstream Bio in Healthcare and Vicore Pharma AB in Health Care.
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Healthcare · Biotechnology · 75 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
UPB vs VCRE FAQ
Which is bigger, Upstream Bio or Vicore Pharma AB?
Upstream Bio (UPB) is larger, with a market capitalization of $249.21M compared with $248.41M for Vicore Pharma AB (VCRE).
Are Upstream Bio and Vicore Pharma AB in the same industry?
No. Upstream Bio is in the Healthcare sector, while Vicore Pharma AB is in Health Care.